ライフサイエンスコーパス: nevirapine

1 ther weak synergy (efavirenz) or antagonism (nevirapine).

2 nant women following single-dose intrapartum nevirapine.

3 e or emtricitabine) with either efavirenz or nevirapine.

4 6 months of age who had no prior exposure to nevirapine.

5 ong young children with no prior exposure to nevirapine.

6 reatment with zidovudine and lamivudine plus nevirapine.

7 exposure and clearance for efavirenz but not nevirapine.

8 6 months after they had received single-dose nevirapine.

9 than did women without previous exposure to nevirapine.

10 fter receipt of a single, peripartum dose of nevirapine.

11 utant associated with clinical resistance to nevirapine.

12 oncentrations after a single 2-mg/kg dose of nevirapine.

13 =48 weeks of treatment with extended-release nevirapine.

14 efavirenz and 2.01 (95% CI, 1.36-2.98) with nevirapine.

15 49); saquinavir/ritonavir, 0.64 (0.23-1.80); nevirapine, 1.65 (0.90-3.02); and abacavir, 1.82 (0.73-4

16 women without prior exposure to single-dose nevirapine, 34 of 249 in the nevirapine group (14%) and

17 retroviral (4%, 3-6; p=0.0273) or the infant-nevirapine (4%, 2-5; p=0.0027) groups.

18 ive molecules, such as diflufenican (44) and nevirapine (45).

19 ant factors (breast-feeding duration, infant nevirapine administration, gestational age, and birth we

20 s are nearly as active as the antiviral drug nevirapine against a variety of clinical isolates in hum

21 The IC50 value for inhibition by nevirapine against wild-type (WT) RT in our removal assa

22 treatment, 112 had received a single dose of nevirapine and 106 had received placebo.

23 ine began the study treatments (121 received nevirapine and 120 received ritonavir-boosted lopinavir)

24 Infants received single-dose nevirapine and 4 weeks of zidovudine.

25 A (short course zidovudine with single-dose nevirapine and an ARV "tail") and B (combination ART dur

26 to the nonnucleoside RT inhibitors (NNRTIs) nevirapine and delavirdine.

27 own to predict increased steady-state plasma nevirapine and efavirenz exposure.

28 g the activity of this inhibitor relative to nevirapine and efavirenz in cell culture.

29 and the pharmacokinetics of single doses of nevirapine and efavirenz.

30 B6 polymorphisms and the pharmacokinetics of nevirapine and efavirenz.

31 ct the steady-state plasma concentrations of nevirapine and efavirenz.

32 rug therapy, treatment with a single dose of nevirapine and interruption of treatment.

33 ions and exhibit a qualitative dependence on nevirapine and ionic strength (KCl) that is similar to t

34 ibine were ENT1 and ENT2 substrates, whereas nevirapine and lexibulin were ENT1 and ENT2 nontransport

35 mutations commonly arise in the presence of nevirapine and result in resistance to the drug.

36 Extended prophylaxis with nevirapine or with nevirapine and zidovudine for the first 14 weeks of life

37 Extended prophylaxis with nevirapine or with nevirapine and zidovudine significantly reduces postnata

38 to age 14 weeks; or the control regimen plus nevirapine and zidovudine to age 14 weeks.

39 ld increased cross-resistance to etravirine, nevirapine, and efavirenz compared with wild type HIV-1

40 otyping and drug concentrations (lamivudine, nevirapine, and efavirenz) were measured on stored sampl

41 o cyclosporine, has increased sensitivity to nevirapine, and is impaired in macrophage infection prio

42 retroviral (ARV) drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside resistance i

43 ine in maternal-antiretroviral, 13 in infant-nevirapine, and six in control groups).

44 onnucleoside reverse-transcriptase inhibitor nevirapine, and the antibiotic TMP-SMX were assessed for

45 l status, NRTIs used, receipt of single-dose nevirapine, and treatment for tuberculosis.

46 HIV-1 inhibitory concentrations of nevirapine are achieved in breast-feeding infants of mot

47 nscriptase inhibitors (NNRTIs) efavirenz and nevirapine are commonly used in first-line antiretrovira

48 z: ART-naive GMR, 0.43; 90% CI, .42, .44 and nevirapine: ART-naive GMR, 1.14; 90% CI, 1.14, 1.16).

49 z: ART-naive GMR, 0.53; 90% CI, .50, .55 and nevirapine: ART-naive GMR, 1.35; 90% CI, 1.29, 1.43).

50 These data support nevirapine as a component of presumptive HIV treatment i

51 Cox regression models with nevirapine as a time-varying covariate, stratified by tr

52 Botswana, the use of efavirenz compared with nevirapine as initial antiretroviral treatment was assoc

53 who either had or had not taken single-dose nevirapine at least 6 months before enrollment were rand

54 cal Trials Group study A5207, women received nevirapine at onset of labor and were randomly assigned

55 Nevirapine at the dose studied was confirmed to be safe

56 ya, antiretroviral therapy (ART) use, mostly nevirapine based, was associated with lower cure rates o

57 ety and therapeutic drug concentrations of a nevirapine-based antiretroviral regimen in the early neo

58 We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadminist

59 eptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens.

60 ve cohort study included patients initiating nevirapine-based antiretroviral therapy (ART) with eithe

61 Nevirapine-based antiretroviral therapy is the predomina

62 r rates of virologic failure with subsequent nevirapine-based antiretroviral therapy than did women w

63 However, this applied only when nevirapine-based antiretroviral therapy was initiated wi

64 We studied the response to nevirapine-based antiretroviral treatment among women an

65 (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20).

66 viremia after interruption of efavirenz- or nevirapine-based ART affects outcomes once these drugs a

67 In contrast, nevirapine-based ART did not adversely affect levonorges

68 PV/r-based ART compared with children taking nevirapine-based ART following AL treatment (15.3% vs 35

69 , children <12 months of age were started on nevirapine-based ART if they were eligible, and randomiz

70 contraceptive method and efavirenz-based or nevirapine-based ART regimen.

71 1 per 100 person-years (95% CI 0.72-1.5) for nevirapine-based ART users and 3.3 per 100 person-years

72 .5 per 100 person-years (95% CI 3.7-5.2) for nevirapine-based ART users and 5.4 per 100 person-years

73 f contraceptive failure than did those using nevirapine-based ART, these women still had lower contra

74 hildren taking LPV/r-based ART compared with nevirapine-based ART.

75 /mL (hazard ratio, 1.39 [CI, 1.14 to 1.70]), nevirapine-based regimen (hazard ratio, 1.43 [CI, 1.16 t

76 Switching children once suppressed to a nevirapine-based regimen might be a valuable treatment o

77 s (2.1 vs 11.7 mg/dL, P < .001); patients on nevirapine-based regimens had a higher increase in HDL c

78 of switching nevirapine-exposed children to nevirapine-based treatment after effective suppression o

79 to compare long-term viral suppression with nevirapine-based versus protease-inhibitor-based (ritona

80 nodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretrov

81 41 women who had been exposed to single-dose nevirapine began the study treatments (121 received nevi

82 ith prior exposure to peripartum single-dose nevirapine (but not in those without prior exposure), ri

83 A single dose of nevirapine can establish antiretroviral resistance withi

84 CI 5-10) of 438 infants but did not lead to nevirapine cessation in any neonates; neutropenia (25 [6

85 1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis.

86 Structure of an RT-DNA-nevirapine complex revealed how NNRTI binding forbids RT

87 s developed from dried blood spot and plasma nevirapine concentrations at study weeks 1 and 2.

88 In Monte-Carlo simulations, week 1 nevirapine concentrations exceeded 3 mug/mL in 80% of te

89 Measured dried blood spot nevirapine concentrations were higher than the minimum H

90 RT in the presence and absence of the NNRTI nevirapine (cumulative total simulation time, 360 ns).

91 ociated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01), and K103N, V106M, and

92 Intrapartum single-dose nevirapine decreases mother-to-child transmission of hum

93 ent with the reverse transcriptase inhibitor nevirapine delayed uncoating in both assays.

94 Maternal receipt of nevirapine did not predict early MTCT in the BF group (P

95 three HIV drugs, (Indinavir, Zidovudine, and Nevirapine), discovered unique interaction features betw

96 clinically relevant treatment levels, while nevirapine does not.

97 eoside reverse transcriptase inhibitors plus nevirapine dosed at 6 mg/kg twice daily for term neonate

98 al triple antiretroviral treatment or infant nevirapine during breastfeeding.

99 A single dose of nevirapine during labor reduces perinatal transmission o

100 , zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug gro

101 nucleoside reverse transcriptase inhibitors (nevirapine, efavirenz).

102 ed stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

103 Among Indians, slower nevirapine elimination was associated with CYP2B6 516G -

104 ir/ritonavir were associated with more rapid nevirapine elimination.

105 prophylactic efficacy, darunavir, efavirenz, nevirapine, etravirine and rilpivirine could more potent

106 present the long-term outcomes of switching nevirapine-exposed children to nevirapine-based treatmen

107 pe) and 155 age-, sex- and ethnicity-matched nevirapine-exposed controls.

108 decrease as the interval between single-dose nevirapine exposure and the start of antiretroviral ther

109 Nevirapine exposure was assessed in all patients with av

110 A population pharmacokinetic model to assess nevirapine exposure was developed from dried blood spot

111 report the secondary outcomes of the study: nevirapine exposures in study weeks 1 and 2 and treatmen

112 plus daily extended prophylaxis either with nevirapine (extended nevirapine) or with nevirapine plus

113 Four daily regimens were compared: nevirapine for 6 weeks, 14 weeks, or 28 weeks, or nevira

114 ut confirmed in-utero HIV infection received nevirapine for a median of 13 days (IQR 7-14).

115 research evaluating the use of efavirenz and nevirapine for pediatric patients.

116 children with prior exposure to single-dose nevirapine for perinatal prevention of HIV transmission,

117 Women received zidovudine and single dose nevirapine for PMTCT and were followed until 12 months p

118 han 24 months who were previously exposed to nevirapine for prevention of mother-to-child transmissio

119 efficacy of efavirenz in children exposed to nevirapine for prevention of mother-to-child transmissio

120 Among HIV-infected children exposed to nevirapine for prevention of mother-to-child transmissio

121 rolling 300 HIV-infected children exposed to nevirapine for prevention of mother-to-child transmissio

122 This study aims to establish dosing of nevirapine for very early treatment of HIV-exposed neona

123 RT and its interaction with the bound NNRTI nevirapine, for both wild-type and mutant (V106A, Y181C,

124 irus (HIV) in resource-limited settings, but nevirapine frequently selects for resistant virus in mot

125 to single-dose nevirapine, 34 of 249 in the nevirapine group (14%) and 36 of 251 in the ritonavir-bo

126 group, as compared with 5.2% in the extended-nevirapine group (P<0.001) and 6.4% in the extended-dual

127 efined toxicity end point was shorter in the nevirapine group (P=0.04), as was the time to death (P=0

128 nificantly between the placebo group and the nevirapine group among 158 women starting antiretroviral

129 ed without prior virologic failure (4 in the nevirapine group and 1 in the ritonavir-boosted lopinavi

130 Virologic failure occurred in 37 (28 in the nevirapine group and 9 in the ritonavir-boosted lopinavi

131 women in the placebo group and 41.7% in the nevirapine group had virologic failure (P<0.001).

132 Significantly more women in the nevirapine group reached the primary end point than in t

133 ry end point was significantly higher in the nevirapine group than in the ritonavir-boosted lopinavir

134 More children in the nevirapine group than in the ritonavir-boosted lopinavir

135 tment (15 in the placebo group and 15 in the nevirapine group).

136 ernal-antiretroviral group, 25 in the infant-nevirapine group, and 38 in the control group became HIV

137 rnal-antiretroviral group, 680 in the infant-nevirapine group, and 542 in the control group.

138 maternal-antiretroviral group, two in infant-nevirapine group, six in control group).

139 d 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GM

140 d 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GM

141 No pregnancies occurred in the ART-naive or nevirapine groups.

142 and 34/39 (87.2%) patients showed measurable nevirapine (>0.25 ng/ml) or efavirenz (>5 ng/ml) concent

143 % CI, 22.0%-31.1%) initiating treatment with nevirapine had virological failure.

144 resource-limited countries, a single dose of nevirapine has been widely prescribed to pregnant women

145 tified 117 HIV-infected Malawian adults with nevirapine hypersensitivity (15 drug-induced liver injur

146 tigen (HLA) markers that are associated with nevirapine hypersensitivity.

147 ositive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clonal, and si

148 ceptibility was reduced in 93% for efavirenz/nevirapine, in 81% for lamivudine/emtricitabine, in 59%

149 quantify two different drugs, lapatinib and nevirapine, in dosed tissues from nonclinical species an

150 e contributed to the suboptimal results with nevirapine include elevated viral load at baseline, sele

151 Nevirapine increased the risk of TAMs, K65R, and Q151M.

152 s within the HLA-DQB1 loci protected against nevirapine-induced hypersensitivity phenotypes.

153 JS/TEN, 20 hypersensitivity syndrome, and 46 nevirapine-induced rash plus 3 with both DILI and SJS ph

154 ed HLA-C*04:01 carriage as a risk factor for nevirapine-induced SJS/TEN in a Malawian HIV cohort.

155 ential for beneficial and adverse effects of nevirapine ingestion.

156 However, nevirapine is associated with a 6%-10% risk of developin

157 Nevirapine is metabolized by cytochrome P450 (CYP) 2B6 a

158 Single-dose nevirapine is the cornerstone of the regimen for prevent

159 onnucleoside reverse transcriptase inhibitor nevirapine is the cornerstone of treatment for human imm

160 n who have had prior exposure to single-dose nevirapine is unknown.

161 Since nevirapine is used for both treatment and perinatal prev

162 r-emtricitabine or tenofovir-lamivudine plus nevirapine is used in many resource-constrained settings

163 Median breast-milk concentrations of nevirapine, lamivudine, and zidovudine were 0.67, 3.34,

164 inhibitory concentration (IC50), and week 5 nevirapine level below the quantification limit.

165 Plasma nevirapine level was quantified on postpartum day 1 and

166 n plasma drug exposure following single-dose nevirapine may be greater for CYP2B6 983T --> C than for

167 nt HIV-1 after administration of single-dose nevirapine may not differ substantially according to CYP

168 All mothers and infants received one dose of nevirapine (mother 200 mg; infant 2 mg/kg) and 7 days of

169 epileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n =

170 triple antiretroviral (n=849); daily infant nevirapine (n=852); or control (n=668).

171 after receiving placebo or a single dose of nevirapine, no women in the placebo group and 41.7% in t

172 1 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1.15; 95% CI,

173 DF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricitabine (FTC)/NVP (

174 duce RNase H cleavage, enhance resistance to nevirapine (NVP) and delavirdine (DLV), but not to efavi

175 ials compared lopinavir/ritonavir (LPV/r) to nevirapine (NVP) for antiretroviral therapy and showed a

176 d in some women who receive single-dose (SD) nevirapine (NVP) for prevention of HIV-1 mother-infant t

177 immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention of mother-to-child trans

178 eriority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretroviral therapy (ART), regard

179 ptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (A

180 Nevirapine (NVP) is widely used in antiretroviral treatm

181 Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human

182 Nevirapine (NVP) resistance emerges in up to 70% of wome

183 We analyzed the development of nevirapine (NVP) resistance in human immunodeficiency vi

184 ligation assay (OLA) to probe for low-level nevirapine (NVP) resistance mutations K103N and Y181C in

185 Single-dose (SD) nevirapine (NVP) significantly reduces mother-to-child t

186 structures of RT-RNA/DNA-dATP and RT-RNA/DNA-nevirapine (NVP) ternary complexes at 2.5 and 2.9 A reso

187 50-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHNVP) has been i

188 The interaction of the NNRTI nevirapine (NVP) with HIV-1 reverse transcriptase (RT) i

189 Nevirapine (NVP), is an HIV-1 antiretroviral with treatm

190 Additionally, we showed that another NNRTI, nevirapine (NVP), stimulated K101E+G190S virus replicati

191 Acquisition of nevirapine (NVP)-resistant human immunodeficiency virus

192 Low-frequency nevirapine (NVP)-resistant variants have been associated

193 er-to-child transmission of HIV-1 can select nevirapine (NVP)-resistant variants, but the frequency,

194 hemical mechanism of resistance to the NNRTI nevirapine (NVP).

195 irological failure than were those receiving nevirapine (odds ratio 0.37, 95% CI 0.22-0.62; p<0.0001)

196 NRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on the integrity of the blood-brain barrier,

197 ren of these women received either 1 dose of nevirapine or 1 dose of nevirapine plus 1 week of daily

198 In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine,

199 ce interval [CI] 1.52, 38.30; p = 0.01) with nevirapine or efavirenz concentrations above vs. below t

200 one antiretroviral therapy (ART) with either nevirapine or efavirenz have suggested poorer virologica

201 Moreover, it attenuated resistance to nevirapine or efavirenz imparted by NNRTI mutations.

202 side reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa.

203 ere associated with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs

204 ation paediatric tablets with lamivudine and nevirapine or efavirenz.

205 mly assigned to a single, peripartum dose of nevirapine or placebo in a trial in Botswana involving t

206 s received zidovudine as well as single-dose nevirapine or placebo.

207 fants were randomized to receive single-dose nevirapine or placebo.

208 ment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted lopinavir in HIV-infecte

209 y with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted lopinavir in HIV-infecte

210 al therapy with tenofovir-emtricitabine plus nevirapine or tenofovir-emtricitabine plus lopinavir boo

211 Extended prophylaxis with nevirapine or with nevirapine and zidovudine for the fir

212 Extended prophylaxis with nevirapine or with nevirapine and zidovudine significant

213 prophylaxis either with nevirapine (extended nevirapine) or with nevirapine plus zidovudine (extended

214 % of those who had received a single dose of nevirapine (P=0.002).

215 children had HIVDR that was associated with nevirapine perinatal exposure (P < .001).

216 ved either 1 dose of nevirapine or 1 dose of nevirapine plus 1 week of daily doses of zidovudine.

217 signed to one of three regimens: single-dose nevirapine plus 1 week of zidovudine (control regimen) o

218 eceive a either control regimen (single-dose nevirapine plus 1 week of zidovudine); the control regim

219 bic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week postpartum "tail" of tenof

220 plus tenofovir-emtricitabine was superior to nevirapine plus tenofovir-emtricitabine for initial anti

221 ith nevirapine (extended nevirapine) or with nevirapine plus zidovudine (extended dual prophylaxis) u

222 apine for 6 weeks, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks.

223 en, 4.8% (95% CI, 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.

224 than 200 cells per cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational

225 re pooled to estimate the efficacy of infant nevirapine prophylaxis to prevent breast-milk HIV-1 tran

226 al triple-antiretroviral prophylaxis, infant-nevirapine prophylaxis, or neither) factorial design.

227 sensitivity issues were possibly related to nevirapine prophylaxis, supporting additional birth PoC-

228 with HIV who have been previously exposed to nevirapine prophylaxis.

229 hat included children exposed to single-dose nevirapine prophylaxis.

230 possibly because of viral suppression under nevirapine prophylaxis.

231 ad received LPV/r, but was lower among prior nevirapine recipients.

232 pinavir/ritonavir, but was lower among prior nevirapine recipients.

233 eased lumefantrine exposure by 2.1-fold; and nevirapine reduced artemether exposure only.

234 Single-dose nevirapine reduces intrapartum human immunodeficiency vi

235 Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human

236 ount and infant birth weight, indicated that nevirapine reduces the rate of HIV-1 infection by 71% (9

237 and 1.8% (95% CI, 1.0%-3.1%) for the 28-week nevirapine regimen (log-rank test for trend, P < .001).

238 nce interval [CI], 4.3%-7.9%) for the 6-week nevirapine regimen, 3.7% (95% CI, 2.5%-5.4%) for the 14-

239 en, 3.7% (95% CI, 2.5%-5.4%) for the 14-week nevirapine regimen, 4.8% (95% CI, 3.5%-6.7%) for the 14-

240 Nevirapine resistance after exposure to the drug for pre

241 sequencing of baseline plasma samples showed nevirapine resistance in 33 of 239 women tested (14%).

242 OLA detected nevirapine resistance in more specimens than consensus s

243 sent in each blood sample (mean, 162 cells), nevirapine resistance mutations (K103N and G190A) were d

244 irus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants.

245 The proportion of women whose nevirapine resistance was detected by OLA 10 days after

246 Nevirapine resistance was found in 7/16 (43.5%) HIV-1-po

247 evated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside

248 deficiency virus type 1 (HIV-1) but promotes nevirapine resistance.

249 These viruses were then analyzed for nevirapine resistance.

250 stant (UCR), efavirenz-resistant (EFVR), and nevirapine-resistant (NVPR) strains in a variety of micr

251 Nevirapine-resistant HIV-1 genotypes (with the mutations

252 the importance of understanding the decay of nevirapine-resistant mutants.

253 potentially lifelong risk of reemergence of nevirapine-resistant virus and highlights the need for s

254 iciency virus type 1 (HIV-1) but selects for nevirapine-resistant virus.

255 oncentration had no effect on removal by the nevirapine-resistant Y181C mutant.

256 Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for th

257 y after they receive intrapartum single-dose nevirapine (SD-NVP).

258 herapy (ART) in women exposed to single-dose nevirapine (sdNVP) >/= 6 mo earlier, the primary endpoin

259 Single-dose nevirapine (sdNVP) for prevention of mother-to-child tra

260 Single-dose nevirapine (sdNVP) given to prevent mother-to-child-tran

261 A single dose of nevirapine (sdNVP) to prevent mother-to-child transmissi

262 TCT regimens were evaluated: (1) single-dose nevirapine (sdNVP), (2) WHO 2010 guidelines' "Option A"

263 Single-dose nevirapine (sdNVP)-based regimens reduce mother-to-child

264 rdant care for 4 PMTCT regimens: single-dose nevirapine (sdNVP); WHO-recommended Option A, WHO-recomm

265 fected cohorts of the Six Week Extended-Dose Nevirapine (SWEN) Study, a study comparing extended nevi

266 95% confidence interval [CI], 1.11-2.84) and nevirapine/tenofovir (27% vs 11%; AOR, 2.09; 95% CI, 1.2

267 or emtricitabine with efavirenz/tenofovir or nevirapine/tenofovir.

268 re infants who had received a single dose of nevirapine than in infants who had received placebo (P<0

269 t-line regimen of stavudine, lamivudine, and nevirapine the benefits of viral load or CD4 cell count

270 from treatment of HIV-infected patients with nevirapine, the first-in-class drug still widely used, e

271 of whether there has been prior exposure to nevirapine, the performance of nevirapine versus ritonav

272 "Option A" (zidovudine in pregnancy, infant nevirapine throughout breastfeeding for women without ad

273 ounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had diffe

274 eek of zidovudine); the control regimen plus nevirapine to age 14 weeks; or the control regimen plus

275 s of age in a prior clinical trial comparing nevirapine to lopinavir/ritonavir (International Materna

276 fter administration of a 200-mg oral dose of nevirapine to nonpregnant, HIV-negative African American

277 Women who received a single dose of nevirapine to prevent perinatal transmission of HIV-1 ha

278 as compared with zidovudine and single-dose nevirapine to prevent transmission of the human immunode

279 t-line regimen of stavudine, lamivudine, and nevirapine to second-line antiretroviral treatment.

280 Studies evaluating daily nevirapine to the breastfeeding infant suggest protectio

281 ical trials indicate daily administration of nevirapine to the infant can prevent breast-milk HIV-1 t

282 aring extended nevirapine versus single-dose nevirapine, to reduce MTCT of HIV among breast-fed infan

283 Among the nevirapine-treated children with virologic failure for w

284 d mothers) within the Six-Week Extended-Dose Nevirapine trial.

285 ty variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNR

286 r exposure to nevirapine, the performance of nevirapine versus ritonavir-boosted lopinavir in young c

287 ine (SWEN) Study, a study comparing extended nevirapine versus single-dose nevirapine, to reduce MTCT

288 and an extended release version of the NNRTI nevirapine, (Viramune XR((R))) were recent additions to

289 clinical trial with peripartum (single-dose nevirapine vs placebo) and postpartum infant feeding (fo

290 e also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 su

291 Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype,

292 The median infant serum concentration of nevirapine was 971 ng/mL, at least 40 times the 50% inhi

293 ivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure i

294 Baseline resistance to nevirapine was detected in 18 of 148 children (12%) and

295 Susceptibility to the NNRTIs efavirenz and nevirapine was inversely proportional to the level of en

296 Rather, a approximately 83-fold increase in nevirapine was required to decrease the rate of removal

297 children (5.2%; 95% CI, 3.2%-7.9%) receiving nevirapine who never achieved virological suppression.

298 e inhibitors were associated with higher and nevirapine with lower IL-6 levels.

299 *58:01, and both amoxicillin-clavulanate and nevirapine with multiple class I and II alleles.

300 efavirenz-containing regimens to twice-daily nevirapine with separate companion pills because of inte

301 (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis).